Cytosorbents (CTSO) Reports Q4 Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro softer after ECB stands pat on rates
CytoSorbents Announces 2020 Financial and Operational Results
March 9, 2021 4:15 PM ESTMONMOUTH JUNCTION, N.J., March 9, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, achieves record Total Revenue and CytoSorb® sales in 2020, and record Product Gross Margins in Q4 2020.
... More